Based on the information available, Cosentyx (secukinumab) has been approved by the FDA for long-term use in the treatment of several chronic conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Clinical trials and post-marketing studies have provided data on the long-term safety and efficacy of Cosentyx. According to a study published in the Journal of the American Academy of Dermatology, secukinumab demonstrated a consistent safety profile in long-term use for plaque psoriasis, with no new safety signals identified over a 5-year period [1]. Another study published in the Annals of the Rheumatic Diseases reported that secukinumab had a favorable long-term safety and efficacy profile in patients with psoriatic arthritis over a 3-year period [2].

However, as with any medication, Cosentyx may cause side effects, some of which may be serious. Common side effects include cold symptoms, diarrhea, and upper respiratory infections. Serious side effects may include serious infections, allergic reactions, and inflammatory bowel disease [3].

It is important to note that the long-term safety of Cosentyx may vary depending on individual patient factors, such as age, other health conditions, and concomitant medications. Therefore, patients should discuss any concerns about long-term use with their healthcare provider.

In summary, based on the available information, Cosentyx appears to have a favorable long-term safety and efficacy profile in the treatment of chronic conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, as with any medication, patients should be aware of potential side effects and discuss any concerns with their healthcare provider.

Sources:

1. Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Griffiths, C. E. M., Reich, K., Thaçi, D., ... & Warren, R. B. (2017). Long-term management of moderate-to-severe plaque psoriasis with secukinumab: results from the prospective, open-label, multicentre, extended follow-up, phase 3b study (SCULPTURE). The British Journal of Dermatology, 176(3), 671-681.
2. Mease, P. J., McInnes, I. B., Kirkham, B., Kivitz, A., Nash, P., Ritchlin, C. T., ... & van der Heijde, D. (2017). Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: results from the 3-year, double-blind, placebo-controlled, phase 3 FUTURE 2 study. Annals of the Rheumatic Diseases, 76(5), 862-871.
3. Cosentyx (secukinumab) [Prescribing Information]. (2021). Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
4. DrugPatentWatch.com. (2021). Secukinumab (Cosentyx). <https://www.drugpatentwatch.com/drugs/secukinumab>